Stallergenes Greer, a global leader in allergy therapeutics, will present positive results from its SPEED survey at the upcoming CFA congress in Paris (France) April 15-18, 2025. The survey highlights both the impact of the iPUMP connected assistant and its strong adoption among patients undergoing sublingual liquid allergen immunotherapy (SLIT) treatment.
Health Technology Insights: Your Behavioral Health Appoints Matthew Zubiller as Chief Executive Officer
iPUMP, developed in conjunction with Aptar Digital Health, supports adherence to Stallergenes Greer’s personalised SLIT treatments, by ensuring patients adopt the correct dosing technique, duration and frequency of treatment. This innovative and easy-to-use tool is connected to a companion mobile application and provides direct access to the treatment protocol prescribed to each patient by their physician.
The two-step SPEED survey, which measured the impact of the iPUMP on patient adherence and observance to SLIT treatment, showed a 15% increase in observance for patients using iPUMP.
Moreover, for children aged 5-12, parental involvement in treatment administration dropped from 50% to 28% over three months, while the proportion of children independently taking their medication rose from 24% to 58%. Notably, 90% of parents felt reassured by the connected assistant, with half feeling completely at ease with treatment administration, compared to 36% in the non-iPUMP® group.
Health Technology Insights: Inbiome Shatters Diagnostic Delays: IVDR-Certified Platform IDs Bacteria in 5 Hours Across EU Hospitals
“Findings of the SPEED survey underscore the role of connected health solutions in improving both treatment adherence and patient confidence, which are key elements in achieving successful therapeutic outcomes,” said Elena Rizova, Chief Medical Officer. “Innovation is at the heart of what we do and iPUMP®, by catering to the needs expressed by patients and healthcare professionals, meets their expectations and provides a solution to enhance treatment management and overall allergy care.”
Marcus Bates, VP Business Development & Global Head of Respiratory at Aptar Digital Health, commented, “The strong results of the SPEED survey pave the way for wider adoption of digital and connected solutions for allergy management, enabling new patients to access a simple, easy-to-use solution that can help track adherence and stay engaged to achieve better health outcomes.”
By integrating digital health capabilities, Stallergenes Greer continues to drive forward its mission to develop precise, patient-centric solutions which empower individuals and improve treatment outcomes.
The results of the SPEED survey establish a strong foundation for the broader adoption of iPUMP, supporting Stallergenes Greer’s commitment to innovation for the benefit of patients, caregivers and the medical community.
Health Technology Insights: Priyanshu Sharma, ByteBrain Advance Ethical AI Innovation
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
